Contribute Try STAT+ Today

Biotech and pharma companies are racing to develop combinations of immunotherapy drugs to treat cancer more effectively. But new data emerging Wednesday night from clinical trial research abstracts released by the American Society of Clinical Oncology (ASCO) paint a muddled picture.

Even with hints of efficacy, there’s still no convincing proof cancer patients benefit more when experimental immune-boosting drugs are paired with immunotherapy blockbusters like Merck’s Keytruda and Bristol-Myers Squibb‘s Opdivo.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy